Concepedia

Maureen Boyd

MB

Statistics

Publications

11

Citations

609

H-Index

11

Active since

1999

Affiliations

Johnson & Johnson (Australia)(Current)

UNSW Sydney

University of California, Los Angeles

Black AIDS Institute

Calimmune (United States)

Maureen Boyd is an author at Johnson & Johnson (Australia) specializing in life sciences, antiviral therapy, and antiretroviral therapy.

Publications per year

1999–2018

11

Publications

11

Anti-Human Immunodeficiency Virus Hematopoietic Progenitor Cell-Delivered Ribozyme in a Phase I Study: Myeloid and Lymphoid Reconstitution in Human Immunodeficiency Virus Type-1–Infected Patients

Rafael G. Amado, Ronald T. Mitsuyasu, Joseph D. Rosenblatt et al. · Human Gene Therapy · 2004 · 135 citations

, , +15

Long‐term survival and concomitant gene expression of ribozyme‐transduced CD4+ T‐lymphocytes in HIV‐infected patients

Janet L. Macpherson, Maureen Boyd, Allison J Arndt et al. · The Journal of Gene Medicine · 2005 · 103 citations

, , +12

Preclinical safety and efficacy of an anti–HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor

Orit Wolstein, Maureen Boyd, Michelle Millington et al. · Molecular Therapy — Methods & Clinical Development · 2014 · 73 citations · Full text

, , +17

Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector

Bryan Burke, Bernard Levin, Jane Zhang et al. · Molecular Therapy — Nucleic Acids · 2015 · 64 citations · Full text

, , +16

Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing

Kazuo Suzuki, Shin-ichiro Hattori, Katherine Marks et al. · Molecular Therapy — Nucleic Acids · 2013 · 63 citations · Full text

, , +17

1–5 of 11